Certara (NASDAQ:CERT) executives used a discussion at the Leerink Partners global healthcare conference to outline recent ...

If you are looking at Certara and wondering whether the recent share price offers value or just more risk, you are not alone. The stock closed at US$6.65, with a 7 day return of a 5.8% decline, a 30 ...

Certara, Inc. (NASDAQ:CERT) is one of the 14 oversold value stocks to invest in right now. Certara, Inc. (NASDAQ:CERT) enjoys ...

Certara’s latest earnings call painted a cautiously balanced picture for investors. Management highlighted solid full-year metrics, including healthy revenue growth, expanding software sales and ...

Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of ...

(Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S ...

Pharmaceutical biosimulation software company Certara won an R&D 100 Award from R&D World magazine for its its Simcyp COVID-19 Vaccine Model. The nearly 50-year-old worldwide competition lists the top ...

Leerink Global Healthcare Conference 2026 March 9, 2026 8:00 AM EDTCompany ParticipantsJohn Gallagher - SVP, Principal ...

Princeton-based Certara, a model-informed drug development and decision support company, announced Wednesday it is celebrating the 20th anniversary of its Simcyp Consortium. According to Certara, the ...

Also Read: What’s Going On With Charles River, Certara, Simulations Plus Stocks On Friday? Certara CEO William F. Feehery noted that the board’s recent $100 million repurchase authorization reflects ...

Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of ...